American Heart Journal
Volume 149, Issue 5 , Pages 832-839 , May 2005

Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment

  • Ignatios Ikonomidis, MD, FESC

      Affiliations

    • Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Athens, Greece
    • Corresponding Author InformationReprint requests: Ignatios Ikonomidis, MD, FESC, Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Perikleous 19, N. Chalkidona, Athens, 14343 Greece.
    • ,
  • John Lekakis, MD, FESC

      Affiliations

    • Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Athens, Greece
    • ,
  • Georgia Vamvakou, MD

      Affiliations

    • Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Athens, Greece
    • ,
  • Felicita Andreotti, MD, PhD, FESC

      Affiliations

    • Imperial College School of Medicine, National Heart and Lung Institute, Cardiology Department, Hammersmith Hospital, London, United Kingdom
    • ,
  • Petros Nihoyannopoulos, MD, FRCP, FACC, FESC

      Affiliations

    • Imperial College School of Medicine, National Heart and Lung Institute, Cardiology Department, Hammersmith Hospital, London, United Kingdom

Received 27 May 2004 ,Accepted 24 August 2004.

References 

  1. Francus T. IL1, IL6 and PDGF mRNA expression in alveolar cells following stimulation with tobacco-derived antigen. Cell. Immunol. 1992;145:156–174
  2. Rose RM, Kozbik L, Filderman AE, et al. Characterisation of colony stimulating factor activity in the human respiratory tract. Comparison of healthy smokers and non smokers. Am. Rev. Respir. Dis. 1992;145:394–399
  3. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low density lipoproteins. Nature (Lond.). 1990;344:254–257
  4. Roth P, Stanley ER. The biology of CSF-1 and its receptor. In: Current topics in microbiology and immunology. 181:Berlin: Sonneg-Verlag; 1992;p. 141–158
  5. Yesner LM, Huh HY, Pearse SF, et al. Regulation of monocyte CD36 and thrombospondin expression by soluble mediators. Arterioscler. Thromb. Vasc. Biol. 1996;16:1019–1025
  6. Silverstein RL, Nachman RL. Thrombospondin binds to monocyte-macrophages and mediates platelet monocyte adhesion. J. Clin. Invest. 1987;79:867–874
  7. Orlandi M, Bartolini G, Minghetti L, et al. Prostaglandin and thromboxane biosynthesis in isolated platelet free monocytes. III. The induction of cyclooxygenase by colony stimulating factor-1 prostaglandins. Leukot. Essent. Fatty Acids. 1989;36:101–106
  8. Raines EW, Rosenfeld ME, Ross R. The role of macrophages. In:  Fuster V,  Ross R,  Topol EJ editor. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott Raven Publishers; 1996;p. 539–555
  9. Ellis EF, Oelz O, Robert LJ, et al. Coronary arterial smooth muscle cell contraction by a substance released from platelets: evidence that it is thromboxane A2. Science. 1976;193:1135–1138
  10. Patrono C, Davi G, Giabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc. Med. 1992;2:15–20
  11. Lyberg T, Stanley ER, Prydz H. Colony stimulating factor-1 induces thromboplastin activity in murine macrophages and human monocytes. J. Cell. Physiol. 1987;132:367–370
  12. Narahara N, Enden T, Wiiger M, et al. Polar expression of tissue factor in human umbilical vein endothelial cell. Arterioscler. Thromb. 1994;14:1815–1820
  13. Bauer J, Ganter U, Geiger T, et al. Regulation of interleukin 6 expression in cultured human blood monocytes and monocyte derived macrophages. Blood. 1988;72:1134–1140
  14. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin 6 levels in humans in vivo. Arthritis Reum. 1992;35:982–984
  15. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am. J. Cardiol. 1999;84:1018–1022
  16. Tappia PS, Troughton KL, Langley-Evans SC. Cigarette smoking influences cytokine production and antioxidant defences. Clin. Sci. (Lond.). 1995;88:485–489
  17. Matetzky S, Tani S, Kangavari S, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation. 2000;102:602–604
  18. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–798
  19. Blache D, Bouthillier D, Davignon J. Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalisation by aspirin. Atherosclerosis. 1992;93:179–188
  20. Kukielka GL, Smith CW, Manning A, et al. Induction of interleukin-6 synthesis in the myocardium. Potential role in post-perfusion inflammatory injury. Circulation. 1995;92:1866–1875
  21. Ikonomidis I, Andreotti F, Nihoyannopoulos P. Reduction of daily-life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. Heart. 2004;90:389–393
  22. Juul-Mollers S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421–1425
  23. Aronson DL, Stevan L, Ball AP, et al. Generation of the combined prothrombin peptide (F1.2) during clotting in blood plasma. J. Cin. Invest. 1977;60:1410–1418
  24. Harrats D, et al. Cigarette smoking renders LDL susceptible to peroxidative modification and enhance metabolism by macrophages. Atherosclerosis. 1989;79:245–252
  25. Hulthe J, Wilksrand J, Fagerberg B. Relation between C-reactive protein and intima thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin. Sci. (Lond.). 2001;100:371–378
  26. Ishibashi S, Inaba T, Shimano H, et al. Monocyte colony stimulating factor enhances cholesterol uptake and degradation of acetylated low density lipoproteins and cholesterol esterification in human monocyte derived macrophages. J. Biol. Chem. 1990;265:14109–14117
  27. Sheshiah PN, Keriakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death. The role of macrophage colony stimulating factor and cell contact. Circulation. 2002;105:174–178
  28. Huh HY, Pearce SF, Yesner LM, et al. Regulated expression of CD36 during monocyte to macrophage differentiation: potential role of CD36 in foam cell formation. Blood. 1996;87:2020–2028
  29. Neri Serneri GG, Gensini GF, Poggesi L, et al. The role of extra platelet thromboxane A2 in unstable angina investigated with dual thromboxane A2 inhibitor: importance of activated monocytes. Coron. Artery Dis. 1994;5:137–145
  30. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J. Thromb. Thrombolysis. 2002;13:49–56
  31. Crea F, Monaco C, Lanza GA, et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin. Cardiol. 2002;25:461–466

 This work was supported by Hammersmith Hospital grant RC/259.

 There is no conflict of interest for any of the contributing authors.

PII: S0002-8703(04)00578-2

doi: 10.1016/j.ahj.2004.08.030

American Heart Journal
Volume 149, Issue 5 , Pages 832-839 , May 2005

Article Tools

* Image Usage & Resolution